Company intelligence / Profile preview

Symbrosia

Kailua Kona, Hawaii, United Statessymbrosia.co ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Symbrosia has developed SeaGraze, a red seaweed-based feed additive shown to reduce methane emissions from cattle by over 80%. The product is undergoing regulatory review with the FDA and commercial trials are ongoing. The company expects US regulatory approval by mid–2026 if all goes as planned. Field trials are being conducted with major partners to validate efficacy at scale.

Therapeutic areas: Other
Modalities: Feed additiveMicrobial therapy (seaweed-based, specifically Asparagopsis taxiformis)
Industry: Agriculture & AgTech

Drug pipeline

1 asset

SeaGraze

Commercial

Indications: Livestock methane reduction

Partnerships

Cattlemen's Heritage Beef Company (CHBC)Legacy Beef Co-opTen Corp ConstructionDanone North AmericaOrganic Valley

Beyond the preview

Go deeper on Symbrosia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symbrosia.

Explore the full profile